Growth Metrics

Jazz Pharmaceuticals (JAZZ) Change in Account Payables (2016 - 2025)

Jazz Pharmaceuticals has reported Change in Account Payables over the past 16 years, most recently at -$29.0 million for Q4 2025.

  • Quarterly Change in Account Payables fell 824.15% to -$29.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.9 million through Dec 2025, up 298.53% year-over-year, with the annual reading at $39.9 million for FY2025, 298.53% up from the prior year.
  • Change in Account Payables was -$29.0 million for Q4 2025 at Jazz Pharmaceuticals, down from $62.4 million in the prior quarter.
  • Over five years, Change in Account Payables peaked at $62.4 million in Q3 2025 and troughed at -$32.0 million in Q2 2021.
  • The 5-year median for Change in Account Payables is -$1.6 million (2021), against an average of $3.8 million.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 20493.66% in 2022 and later crashed 1042.52% in 2023.
  • Tracing JAZZ's Change in Account Payables over 5 years: stood at $37.9 million in 2021, then plummeted by 140.72% to -$15.4 million in 2022, then surged by 47.43% to -$8.1 million in 2023, then skyrocketed by 61.31% to -$3.1 million in 2024, then crashed by 824.15% to -$29.0 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$29.0 million, $62.4 million, and -$12.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.